I doubt seriously any BP is "eye rolling" at this point. It's going to come down to the top-line data (I'm still pulling for Capitalism for the US). I would have def done things differently (based on what I know as a shareholder) in his shoes, but I sincerely think he is being cautious based on FDA guidelines they gave him. IMO, last thing we want now is a PR firm (I've been there with OTC Names, and it hasn't turned out good), until data. JMI!